Cardiovascular comorbidities of psoriasis and psoriatic arthritis: A report from the GRAPPA 2012 annual meeting

April W. Armstrong, Joel M. Gelfand, Wolf Henning Boehncke, Ehrin J. Armstrong

Research output: Contribution to journalArticle

17 Scopus citations


At the 2012 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) in Stockholm, Sweden, several GRAPPA members led a panel discussion on cardiovascular (CV) comorbidities of psoriasis and psoriatic arthritis (PsA). The panelists discussed the role of insulin resistance in the pathophysiology of psoriasis, the possible effect of tumor necrosis factor inhibitors on CV comorbidities, and the effect of 12/23 monoclonal antibodies on CV outcomes. The panelists also addressed how lessons from CV comorbidity research could be applied to other areas of comorbidity research in psoriasis and PsA and identified future research directions in this area.

Original languageEnglish (US)
Pages (from-to)1434-1437
Number of pages4
JournalJournal of Rheumatology
Issue number8
StatePublished - Aug 2013



  • Biologics
  • Cardiovascular comorbidities
  • Comparative effectiveness
  • Psoriasis
  • Psoriatic arthritis
  • Tumor necrosis factor inhibitors

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this